Paradigm shift of cancer precision medicine by liquid biopsy

DOI
  • Nakamura Yoshiaki
    Translational Research Support Section, National Cancer Center Hospital East Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East

Bibliographic Information

Other Title
  • リキッドバイオプシーはがんゲノム医療をどう変えるか

Abstract

<p>　Among liquid biopsies, circulating tumor DNA (ctDNA) analysis can identify genomic alterations with high accuracy. A ctDNA gene panel test has been approved in Japan and is expected to be used for cancer precision medicine in the future. In cancer genome profiling, ctDNA analysis has the advantages of faster turnaround time of results and evaluation of heterogeneity of genetic abnormalities compared to tumor tissue analysis. We have launched GOZILA, a ctDNA-based screening study, based on the GI-SCREEN platform, a national gastrointestinal cancer biomarker screening project of SCRUM-Japan. In a large-scale study comparing GOZILA and GI-SCREEN, we have shown that genomic profiling has the advantage of reducing the time to return results and increasing patient enrollment without compromising therapeutic efficacy. We have also experienced cases in which genomic abnormalities that could not be detected by tissue analysis were identified by ctDNA analysis, and therapeutic effects were observed by cancer genomic medicine based on these abnormalities. Based on the usefulness of ctDNA analysis, we are currently conducting a clinical trial of umbrella/basket type in patients with advanced solid tumors.</p>

Journal

Keywords

Details 詳細情報について

  • CRID
    1390573242773732736
  • DOI
    10.18976/jsht.21.4_109
  • ISSN
    24356808
  • Text Lang
    ja
  • Data Source
    • JaLC
  • Abstract License Flag
    Disallowed

Report a problem

Back to top